Sensyne Health to help Bayer develop AI-enabled imaging solutions

Michael Walter | | Health Exec | Precision Medicine

Sensyne Health announced Thursday, Oct. 10, that it has joined Bayer’s newest innovation hub, LifeHub UK, and will work toward developing solutions for automated image evaluation.

Bayer launched LifeHub UK to bring a variety of healthcare companies together for improving “disease detection and data-driven drug discovery” through the development of AI-enabled imaging technologies. Sensyne Health is one of the first companies to join LifeHub UK.

“Initiatives like this are essential to quickly maximize the opportunity AI presents to improve patient care and accelerate medical research,” Lord (Paul) Drayson, PhD, CEO of Sensyne Health, said in a prepared statement. “I’m delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients.”

“We are delighted to launch LifeHub UK,” Kemal Malkin, a member of the Bayer Board of Management, said in the same statement. “We firmly believe that artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalized treatments.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”